Codexis, Inc. (NASDAQ:CDXS) Short Interest Update

Codexis, Inc. (NASDAQ:CDXS) saw a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,680,000 shares, a decrease of 13.8% from the October 31st total of 1,950,000 shares. Based on an average daily trading volume, of 661,400 shares, the short-interest ratio is presently 2.5 days.

Analyst Ratings Changes

A number of analysts have issued reports on CDXS shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price target on shares of Codexis in a report on Friday, November 22nd. Benchmark reaffirmed a “hold” rating on shares of Codexis in a report on Monday, November 4th.

Codexis Trading Up 3.1 %

Shares of CDXS opened at $4.72 on Tuesday. The stock has a market capitalization of $384.10 million, a PE ratio of -5.47 and a beta of 2.07. The company’s fifty day moving average is $3.56 and its 200 day moving average is $3.29. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. Codexis has a fifty-two week low of $1.85 and a fifty-two week high of $4.91.

Codexis (NASDAQ:CDXS) last posted its earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The business had revenue of $12.83 million during the quarter, compared to the consensus estimate of $11.64 million. During the same quarter last year, the firm earned ($0.26) earnings per share. Sell-side analysts expect that Codexis will post -0.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Opaleye Management Inc. acquired 45,000 shares of Codexis stock in a transaction dated Monday, September 23rd. The shares were purchased at an average price of $2.94 per share, for a total transaction of $132,300.00. Following the completion of the transaction, the insider now directly owns 8,435,000 shares in the company, valued at approximately $24,798,900. This represents a 0.54 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders bought 1,166,000 shares of company stock valued at $3,514,910. Company insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Codexis

Institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its holdings in Codexis by 23.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company’s stock valued at $3,399,000 after buying an additional 209,207 shares during the period. abrdn plc boosted its stake in Codexis by 62.5% during the third quarter. abrdn plc now owns 800,410 shares of the biotechnology company’s stock worth $2,465,000 after buying an additional 307,762 shares during the period. GSA Capital Partners LLP increased its position in Codexis by 83.5% during the third quarter. GSA Capital Partners LLP now owns 99,629 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 45,337 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Codexis by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 284,166 shares of the biotechnology company’s stock valued at $881,000 after acquiring an additional 32,138 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Codexis by 3.1% in the 1st quarter. Vanguard Group Inc. now owns 4,258,201 shares of the biotechnology company’s stock worth $14,861,000 after acquiring an additional 129,773 shares during the last quarter. 78.54% of the stock is owned by institutional investors.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.